ArticleEuropean journal of neurology2025

Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group.

Andreas A Argyriou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.